Drug Trial Radar · NCT05234190
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Jan 21, 2022
Primary completion
Feb 25, 2026
Study completion Sep 2040
Sponsor
- Lead sponsor
- Quell Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn.
Conditions
- Rejection; Transplant, Liver
- Liver Failure
- Liver Diseases
Interventions
QEL-001Drug
QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 28 Days post infusion
- Long-term safetyTime frame: Day of infusion through to Week 82 and up to 15 years post infusion
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
H. Saint Luc
Brussels, Belgium
Hopital Erasme
Brussels, Belgium
UZ Leuven
Leuven, Belgium
H. Clinic Barcelona
Barcelona, Spain
Hospital Reina Sofia
Córdoba, Spain
G. Gergorio Maranon
Madrid, Spain
Queen Elizabeth Hospital
Birmingham, United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom
King's College Hospital NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.